Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity

Cardiology (Switzerland)

Volumn 79, Issue 2, 1991, Pages 110-115

  De Leonardis, Vittorio ^a   Bartalucci, Sonia ^a   Cinelli, Piero ^a   De Scalzi, Maurizio ^a   Becucci, Aureliano ^a   Lottini, Giovanni ^a   Neri, Bruno ^a  

^a Istituto di Clinica Medica III   (Italy)

Author keywords

Cardiotoxicity; Chemotherapy; Late potentials; Mitoxantrone; Signal averaged electrocardiography

Indexed keywords

MITOXANTRONE;

ADULT; AFTERDISCHARGE; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; ELECTROCARDIOGRAM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; BREAST NEOPLASMS; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MIDDLE AGE; MITOXANTRONE; MYOCARDIAL DISEASES; PROSPECTIVE STUDIES; RADIONUCLIDE ANGIOGRAPHY; STROKE VOLUME;

EID: 0025767079     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000174867     Document Type: Article

References (21)

1. Henderson BM, Dougherty WJ, James VC, et al: Safety assessment of a new anticancer compound. mitoxantrone, in beagle dogs: Comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 1982;66:1139-1143.
2. Sparano BM, Gordon G, Hall C, et al: Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: Comparison with doxorubicin. II. Histologic and ultrastructural pathology. Cancer Treat Rep 1982;66:1145-1158.
3. Zbinden G, Beilstein AK: Comparison of cardio-toxicity of two anthracenediones and doxorubicin in rats. ToxicolLett1982; 11:289-297.
4. Vorobiof DA, Iturralde M, Falkson G: Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone. Cancer ChemotherPharmacol 1985;15:253-257.
5. Perkins WE, Schroeder RL, Carrano RA, et al: Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig. Cancer Treat Rep 1984;68:841-847.
6. Cassidy J, Merrick MV, Smyth JF, et al: Cardio-toxicity of mitoxantrone assessed by stress and resting nuclear ventriculography. Eur J Cancer ClinOncol 1988;24:935-938.
7. Unverferth DV, Unverferth BJ, Balcerzak SP, et al: Cardiac evaluation of mitoxantrone. Cancer Treat Rep 1983;67:343-350.
8. Simson MB, Untereker WJ, Spielman SR, et al: Relation between late potentials on the body surface and directly recorded fragmented electrograms in patients with ventricular tachycardia. Am J Cardiol 1983;57:105-112.
9. Gomes JA, Mehra R, Barreca P, et al: A comparative analysis of signal averaging of the surface QRS complex and intercardiac and epicardiac recordings of ventricular tachycardia. PACE 1988; 11:271-282.
10. Metha D, Camm AJ: Signal-averaged electrocardiography and the significance of late potentials in patients with 'idiopathic' ventricular tachycardia: A review. ClinCardiol 1989;12:307-312.
11. Boincau JP, Cox JL: Slow ventricular activation in acute myocardial infarction. A source of reentrant premature ventricular contraction. Circulation 1973;48:702-708.
12. Kelen G, Henkin R, Lannon M, et al: Correlation between the signal-averaged electrocardiogram from Holter tapes and from real-time recordings. Am J Cardiol 1989;63:1321-1325.
13. Alexander J, Dainiak N, Berger HJ. et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-283.
14. Robinson BA, Colls BM, Turner JG: Adriamycin cardiotoxicity monitoring by radionuclide scan. Br J Cancer 1983;48:315-317.
15. Gomes JA, Winters SL, Martinson M, et al: The prognostic significance of quantitative signal-averaged variables relative to clinical variables, site of myocardial infarction, ejection fraction and ventricular premature beats: A prospective study. J Am CollCardiol 1989;13:377-384.
16. Gomes JA, Horowitz SL, Milner M, et al: Late potentials in myocardial infarction: Relationship to ejection fraction and wall motion abnormalities. Am J Cardiol 1987;59:1071-1074.
17. Wortman JE, Lucas VS Jr., Pharm BS, et al: Sudden death during doxorubicin administration. Cancer 1979;44:1588-1591.
18. Unverferth DV: Anthracycline-induced heart disease; in Underferth EV (ed): Dilated Cardiomyopathy. New York. Futura Publishing Company. 1985, pp 179-200.
19. El-Sherif N, Ursell SN, Bekheit S, et al: Prognostic significance of the signal-averaged ECG depends on the time of recording in the postinfarction period. Am Heart J 1989; 118:256-264.
20. Commerford PJ, Lloyd EA: Arrhythmias in patients with drug toxicity, electrolyte, and endocrine disturbances. Med Clin North Am 1984;68: 1051-1078.
21. Villani F, Galimberti M, Crippa F: Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone. Drugs Exp Clin Res 1989; 15:501-506.